0001062993-20-006362.txt : 20201215 0001062993-20-006362.hdr.sgml : 20201215 20201215161529 ACCESSION NUMBER: 0001062993-20-006362 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20201215 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20201215 DATE AS OF CHANGE: 20201215 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NERIUM BIOTECHNOLOGY INC CENTRAL INDEX KEY: 0001429040 STANDARD INDUSTRIAL CLASSIFICATION: MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833] IRS NUMBER: 141987900 STATE OF INCORPORATION: Z4 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-54051 FILM NUMBER: 201389767 BUSINESS ADDRESS: STREET 1: 11467 HUEBNER ROAD STREET 2: SUITE 175 CITY: SAN ANTONIO STATE: TX ZIP: 78230 BUSINESS PHONE: 210-822-7908 MAIL ADDRESS: STREET 1: 11467 HUEBNER ROAD STREET 2: SUITE 175 CITY: SAN ANTONIO STATE: TX ZIP: 78230 8-K 1 form8k.htm FORM 8-K Nerium Biotechnology, Inc.: Form 8-K - Filed by newsfilecorp.com

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934

Date of Report (Date of earliest event reported):December 15, 2020

Nerium Biotechnology, Inc.

(Exact name of Registrant as specified in its charter)

Canada

 

000-54051

 

14-1987900

(State or other jurisdiction of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

11467 Huebner Road, Suite 175

San Antonio, TX 78230

(Address of principal executive offices, including zip code)

(210) 822-7908

(Registrant's telephone number, including area code)

Check the appropriate box below if the 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

[  ]

Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

 

[  ]

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

 

[  ]

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

 

[  ]

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

 

Trading Symbol(s)

 

Name of each exchange on which registered

N/A

 

N/A

 

N/A

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2) Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On December 11, 2020, Dan Amadori notified Nerium Biotechnology, Inc. (the "Company") that he was resigning from his position as a member of the Board of Directors, effective that same day.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Nerium Biotechnology, Inc.

 

 

 

Date: December 15, 2020

By:

/s/ Dennis R. Knocke

 

 

Dennis R. Knocke, President and Chief Executive Officer

 

 

Chief Executive Officer